Projects per year
Personal profile
Research interests
Dr. Monika Joshi’s research focus is in the field of genitourinary tumors, particularly in the field of immunotherapy and targeted therapy.
Clinical interests
Dr. Monika Joshi developed clinical and translational expertise in genitourinary malignancies. This experience has positioned her to undertake several innovative clinical trials with multiple collaborations and national participation. She is the disease team co-leader for the genitourinary diseases group at Penn State Cancer Institute. In addition she holds regional and national leadership roles as the co-chair for the genitourinary committee for the Big Ten Cancer Research Consortium and is also as a representative for the Pennsylvania Governor's Advisory Panel on Genetics and Genomics.
Dr. Joshi has a keen interest in developing clinical trials with novel immunotherapeutic combinations and identifying predictive and prognostic biomarkers.
Professional information
Certification, Educational Commission for Foreign Medical Graduates (ECFMG), 2006
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Fellowship, Penn State Health Milton S. Hershey Medical Center
… → 2013
Residency, UPMC Pinnacle
… → 2010
Specialist Registrar (Fellow), University Hospitals Coventry and Warwickshire NHS Trust
… → 2007
MBBS, Manipal Academy of Higher Education
… → 2001
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Projects
- 1 Active
-
Early clinial trials for Angelica herbal supplements for prostate cancer interception
Lu, J. (PI) & Joshi, M. (CoPI)
9/1/22 → 8/31/25
Project: Research project
-
Angelica gigas Nakai (Korean Dang-gui) Root Alcoholic Extracts in Health Promotion and Disease Therapy – active Phytochemicals and In Vivo Molecular Targets
Lü, J., Jiang, C., Drabick, J. J., Joshi, M. & Perimbeti, S., Jan 2025, In: Pharmaceutical Research. 42, 1, p. 25-47 23 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Interferon-γ/Janus Kinase 1/STAT1 Signaling Represses Forkhead Box A1 and Drives a Basal Transcriptional State in Muscle-Invasive Bladder Cancer
Lawrence, S. S., Yamashita, H., Shuman, L., Raman, J. D., Joshi, M., Yochum, G. S., Wu, X. R., Al-Ahmadie, H. A., Warrick, J. I., Walter, V. & DeGraff, D. J., May 2025, In: American Journal of Pathology. 195, 5, p. 1013-1030 18 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)
Tannir, N. M., Formiga, M. N., Penkov, K., Kislov, N., Vasiliev, A., Gunnar Skare, N., Hong, W., Dai, S., Tang, L., Qureshi, A., Zalevsky, J., Tagliaferri, M. A., George, D., Agarwal, N., Pal, S., Marathe, O., Curti, B., Hussain, A., Bilen, M. A. & Pal, S. K. & 93 others, , Aug 10 2024, In: Journal of Clinical Oncology. 42, 23, p. 2800-2811 12 p.Research output: Contribution to journal › Article › peer-review
7 Scopus citations -
Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043
Zakharia, Y., Singer, E. A., Acharyya, S., Garje, R., Joshi, M., Peace, D., Baladandayuthapani, V., Majumdar, A., Li, X., Lalancette, C., Kryczek, I., Zou, W. & Alva, A., Dec 2024, In: Nature communications. 15, 1, 972.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations -
Editorial: Innovative molecular therapeutic approaches in urothelial carcinoma
Holder, S. L., Yin, M. & Joshi, M., 2024, In: Frontiers in Oncology. 14, 1430285.Research output: Contribution to journal › Editorial › peer-review
Open Access